卡培他滨-话题@MedSci

#卡培他滨#

72篇内容 | 3160人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1293530, encodeId=e44612935307f, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索, objectType=article, longId=217525, objectId=c79c21e52563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c79c21e52563, replyNumber=0, likeNumber=66, createdTime=2021-09-25, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c79c21e52563, moduleTitle=Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c79c21e52563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293529, encodeId=e8ed129352937, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Front Oncol：吡咯替尼+长春瑞滨VS拉帕替尼+卡培他滨用于转移性HER-2阳性经治乳腺癌患者的疗效对比：多中心回顾性研究, objectType=article, longId=217280, objectId=228d21e2804b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=228d21e2804b, replyNumber=0, likeNumber=90, createdTime=2021-09-20, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=228d21e2804b, moduleTitle=Front Oncol：吡咯替尼+长春瑞滨VS拉帕替尼+卡培他滨用于转移性HER-2阳性经治乳腺癌患者的疗效对比：多中心回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=228d21e2804b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293528, encodeId=f1bb12935285d, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=J Clin Oncol：卡培他滨维持 vs 治疗中断对一线治疗后病情稳定的转移性结直肠癌患者预后和生活质量的影响, objectType=article, longId=217140, objectId=67cd21e14003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67cd21e14003, replyNumber=0, likeNumber=74, createdTime=2021-09-16, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67cd21e14003, moduleTitle=J Clin Oncol：卡培他滨维持 vs 治疗中断对一线治疗后病情稳定的转移性结直肠癌患者预后和生活质量的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67cd21e14003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293527, encodeId=c444129352ec9, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JNCCN：卡培他滨/替莫唑胺(CAPTEM)治疗神经内分泌肿瘤的疗效和安全性, objectType=article, longId=216808, objectId=6a23216808c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a23216808c1, replyNumber=0, likeNumber=83, createdTime=2021-09-09, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a23216808c1, moduleTitle=JNCCN：卡培他滨/替莫唑胺(CAPTEM)治疗神经内分泌肿瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a23216808c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293526, encodeId=14c8129352634, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究, objectType=article, longId=214070, objectId=468d2140e0fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=468d2140e0fd, replyNumber=0, likeNumber=63, createdTime=2021-07-13, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=468d2140e0fd, moduleTitle=LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=468d2140e0fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293525, encodeId=39541293525f6, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Eur J Cancer：奥沙利铂/卡培他滨联合放疗（OxCapRT）对比紫杉醇/卡铂联合放疗（CarPacRT）新辅助治疗对可切除食管腺癌的疗效和安全性：NeoSCOPE长期随访结果, objectType=article, longId=213266, objectId=96fd2132664f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96fd2132664f, replyNumber=0, likeNumber=67, createdTime=2021-06-27, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96fd2132664f, moduleTitle=Eur J Cancer：奥沙利铂/卡培他滨联合放疗（OxCapRT）对比紫杉醇/卡铂联合放疗（CarPacRT）新辅助治疗对可切除食管腺癌的疗效和安全性：NeoSCOPE长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96fd2132664f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293524, encodeId=b3f9129352400, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet：卡培他滨节拍辅助治疗显著改善晚期鼻咽癌患者的存活预后, objectType=article, longId=212477, objectId=7bca2124e7d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bca2124e7d2, replyNumber=0, likeNumber=75, createdTime=2021-06-10, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bca2124e7d2, moduleTitle=Lancet：卡培他滨节拍辅助治疗显著改善晚期鼻咽癌患者的存活预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bca2124e7d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293523, encodeId=02011293523c9, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JCO:三阴乳腺癌（TNBC）患者新辅助化疗后残留，铂类化疗对比卡培他滨的疗效和安全性：随机III期研究（ECOG-ACRIN EA1131）, objectType=article, longId=212420, objectId=c51c2124203e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c51c2124203e, replyNumber=0, likeNumber=70, createdTime=2021-06-09, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c51c2124203e, moduleTitle=JCO:三阴乳腺癌（TNBC）患者新辅助化疗后残留，铂类化疗对比卡培他滨的疗效和安全性：随机III期研究（ECOG-ACRIN EA1131）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c51c2124203e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293522, encodeId=32df12935224c, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JAMA Oncology：降低奥沙利铂/卡培他滨化疗强度对老年或体弱晚期胃食管癌患者的生活质量和疗效评估：来自GO2 III期随机临床试验结果, objectType=article, longId=211614, objectId=6cbb211614a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cbb211614a4, replyNumber=0, likeNumber=43, createdTime=2021-05-23, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cbb211614a4, moduleTitle=JAMA Oncology：降低奥沙利铂/卡培他滨化疗强度对老年或体弱晚期胃食管癌患者的生活质量和疗效评估：来自GO2 III期随机临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cbb211614a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293521, encodeId=4aaa1293521e6, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=肿瘤病学年鉴：帕洛昔布联合内分泌治疗与卡培他滨治疗转移性乳腺癌的疗效比较, objectType=article, longId=209882, objectId=3ee42098821b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ee42098821b, replyNumber=0, likeNumber=56, createdTime=2021-04-14, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ee42098821b, moduleTitle=肿瘤病学年鉴：帕洛昔布联合内分泌治疗与卡培他滨治疗转移性乳腺癌的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ee42098821b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293520, encodeId=a1ba1293520d2, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JAMA：卡培他滨维持治疗对早期三阴性乳腺癌疗效观察的影响, objectType=article, longId=204500, objectId=b002204500d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b002204500d3, replyNumber=0, likeNumber=80, createdTime=2020-12-16, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b002204500d3, moduleTitle=JAMA：卡培他滨维持治疗对早期三阴性乳腺癌疗效观察的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b002204500d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293519, encodeId=33a612935191f, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌, objectType=article, longId=184670, objectId=4c281846e069, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c281846e069, replyNumber=0, likeNumber=73, createdTime=2019-12-14, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c281846e069, moduleTitle=NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c281846e069)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293518, encodeId=0e731293518b5, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=【2019 ESMO】哌柏西利联合内分泌治疗 vs 卡培他滨治疗HR+/HER2-晚期乳腺癌——疗效优异，生活质量可期, objectType=article, longId=180685, objectId=9c2e180685de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2e180685de, replyNumber=0, likeNumber=77, createdTime=2019-10-10, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2e180685de, moduleTitle=【2019 ESMO】哌柏西利联合内分泌治疗 vs 卡培他滨治疗HR+/HER2-晚期乳腺癌——疗效优异，生活质量可期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c2e180685de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293517, encodeId=b98b129351e04, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Neurology：见于卡培他滨诱发脑白质病的短暂性缄默伴胼胝体压部病变, objectType=article, longId=163311, objectId=fe951633110c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe951633110c, replyNumber=0, likeNumber=70, createdTime=2019-04-01, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe951633110c, moduleTitle=Neurology：见于卡培他滨诱发脑白质病的短暂性缄默伴胼胝体压部病变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe951633110c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293516, encodeId=d6f912935161e, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet oncol：顺铂+卡培他滨联合化疗方案添加雷莫芦单抗并不能延长转移性胃癌患者的无进展存活期, objectType=article, longId=159661, objectId=f84d15966103, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f84d15966103, replyNumber=0, likeNumber=60, createdTime=2019-02-10, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f84d15966103, moduleTitle=Lancet oncol：顺铂+卡培他滨联合化疗方案添加雷莫芦单抗并不能延长转移性胃癌患者的无进展存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f84d15966103)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293515, encodeId=e691129351541, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果, objectType=article, longId=139112, objectId=33c3139112e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33c3139112e3, replyNumber=0, likeNumber=69, createdTime=2018-05-27, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33c3139112e3, moduleTitle=Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33c3139112e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293514, encodeId=d58412935143e, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=EUR J Cancer：卡培他滨联合贝伐单抗在转移性结直肠癌维持治疗中的成本效益分析, objectType=article, longId=125182, objectId=26791251825d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26791251825d, replyNumber=0, likeNumber=88, createdTime=2018-01-01, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26791251825d, moduleTitle=EUR J Cancer：卡培他滨联合贝伐单抗在转移性结直肠癌维持治疗中的成本效益分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26791251825d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293513, encodeId=1f3b1293513b9, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）, objectType=article, longId=124481, objectId=c81c12448125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c81c12448125, replyNumber=0, likeNumber=70, createdTime=2017-12-26, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c81c12448125, moduleTitle=EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c81c12448125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293512, encodeId=3458129351289, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet Gastroen Hepatol：III级结肠癌患者的辅助治疗——氟尿嘧啶S1vs卡培他滨, objectType=article, longId=117531, objectId=fad311e53132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fad311e53132, replyNumber=0, likeNumber=0, createdTime=2017-10-27, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fad311e53132, moduleTitle=Lancet Gastroen Hepatol：III级结肠癌患者的辅助治疗——氟尿嘧啶S1vs卡培他滨, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fad311e53132)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293511, encodeId=9afb12935114f, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JAMA Oncol：指纹就这样在接受卡培他滨化疗后消失了……我是谁？, objectType=article, longId=108837, objectId=76ff10883ec0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76ff10883ec0, replyNumber=0, likeNumber=69, createdTime=2017-08-16, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76ff10883ec0, moduleTitle=JAMA Oncol：指纹就这样在接受卡培他滨化疗后消失了……我是谁？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76ff10883ec0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

卡培他滨

2020-05-29

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索

2021-09-25

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Front Oncol：吡咯替尼+长春瑞滨VS拉帕替尼+卡培他滨用于转移性HER-2阳性经治乳腺癌患者的疗效对比：多中心回顾性研究

2021-09-20

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

J Clin Oncol：卡培他滨维持 vs 治疗中断对一线治疗后病情稳定的转移性结直肠癌患者预后和生活质量的影响

2021-09-16

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JNCCN：卡培他滨/替莫唑胺(CAPTEM)治疗神经内分泌肿瘤的疗效和安全性

2021-09-09

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究

2021-07-13

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Eur J Cancer：奥沙利铂/卡培他滨联合放疗（OxCapRT）对比紫杉醇/卡铂联合放疗（CarPacRT）新辅助治疗对可切除食管腺癌的疗效和安全性：NeoSCOPE长期随访结果

2021-06-27

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet：卡培他滨节拍辅助治疗显著改善晚期鼻咽癌患者的存活预后

2021-06-10

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JCO:三阴乳腺癌（TNBC）患者新辅助化疗后残留，铂类化疗对比卡培他滨的疗效和安全性：随机III期研究（ECOG-ACRIN EA1131）

2021-06-09

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JAMA Oncology：降低奥沙利铂/卡培他滨化疗强度对老年或体弱晚期胃食管癌患者的生活质量和疗效评估：来自GO2 III期随机临床试验结果

2021-05-23

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

肿瘤病学年鉴：帕洛昔布联合内分泌治疗与卡培他滨治疗转移性乳腺癌的疗效比较

2021-04-14

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JAMA：卡培他滨维持治疗对早期三阴性乳腺癌疗效观察的影响

2020-12-16

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌

2019-12-14

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

【2019 ESMO】哌柏西利联合内分泌治疗 vs 卡培他滨治疗HR+/HER2-晚期乳腺癌——疗效优异，生活质量可期

2019-10-10

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Neurology：见于卡培他滨诱发脑白质病的短暂性缄默伴胼胝体压部病变

2019-04-01

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet oncol：顺铂+卡培他滨联合化疗方案添加雷莫芦单抗并不能延长转移性胃癌患者的无进展存活期

2019-02-10

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果

2018-05-27

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

EUR J Cancer：卡培他滨联合贝伐单抗在转移性结直肠癌维持治疗中的成本效益分析

2018-01-01

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）

2017-12-26

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet Gastroen Hepatol：III级结肠癌患者的辅助治疗——氟尿嘧啶S1vs卡培他滨

2017-10-27

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JAMA Oncol：指纹就这样在接受卡培他滨化疗后消失了……我是谁？

2017-08-16

科室
- - 订阅+
  - 更多科室
工具
服务